Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Effect of GnRH analogue on predicted adult height in girls with early puberty

조기사춘기 여아에서 성선자극호르몬 방출호르몬 효능약제가 예측성인신장에 미치는 효과

  • Ahn, Byung-Hoon (Department of Pediatrics, College of Medicine and Medical Research Institute, Chungbuk National University) ;
  • Han, Heon-Seok (Department of Pediatrics, College of Medicine and Medical Research Institute, Chungbuk National University)
  • 안병훈 (충북대학교 의과대학 소아과학교실) ;
  • 한헌석 (충북대학교 의과대학 소아과학교실)
  • Received : 2005.12.29
  • Accepted : 2006.02.27
  • Published : 2006.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : The recent results observed in precocious puberty and the hope that interrupting puberty might increase adult height have led to an attempt to use GnRH agonist(GnRHa) in children with premature puberty and a poor growth prognosis. We aimed to analyze the growth promoting effect of GnRHa in girls with early puberty and low predicted adult height(PAH). Methods : Thirty six girls were recruited. They were grouped according to the GnRHa treatment period(group 1>6 mo, n=18; group 2<6 mo, n=18). The following variables were analyzed before and after GnRHa treatment : chronological age(CA), bone age(BA), ${\Delta}age$(CA-BA), height, target height (TH), PAH, serum IGF-1, IGFBP-3. Results : Duration of the GnRHa treatment was $0.89{\pm}0.81yr$($1.37{\pm}0.92yr$ in group 1, and $0.41{\pm}0.08yr$ in group 2). Before treatment, none of the variables were different between the two groups. There were no differences in the following variables the between two groups at the end of treatment : CA, BA, ${\Delta}age$, PAH, serum IGF-1, IGFBP-3. But, growth velocity(GV) and PAH increment during treatment were significantly reduced in group 1. Compared with initial PAH, PAH at the end of treatment was significantly increased($3.7{\pm}3.2cm$). The last serum levels of IGF-1 and IGFBP-3 were lower than those before treatment. Conclusion : Even though last PAH didn't approach TH, short term GnRHa administration in early puberty with low predicted PAH was somewhat effective. But, GnRHa administration suppressed the growth hormone-IGF-1 axis. Therefore, it is recommended that growth hormone(GH) should be used in combination with GnRHa.

목 적 : 최근 성조숙증에서 사춘기를 중단시킴으로써 성인신장을 증가시킬 수 있으리라는 기대로 조기 사춘기로 인하여 신장에 대한 예후가 불량한 소아에서 성선자극호르몬 방출호르몬 효능약제의 시도가 이루어졌다. 이에 저자들은 조기 사춘기로 예측 성인신장이 저하된 여아에서 이 약제의 신장 증가효과를 분석하고자 하였다. 방 법 : 소아과 외래에 조기 사춘기와 예측성인신장이 저신장으로 예측되는 36명의 여아를 대상으로 GnRHa를 6개월 이상 사용한 제 1군과 6개월 미만 사용한 제 2군으로 나누어 치료 시작시와 치료 후의 역연령, 골연령, 신장 및 표준편차치, 예측성 인신장 및 표준편차치, 표적키 및 표준편차치, 혈청 IGF-1, IGFBP-3 치를 비교하였다. 결 과 : 1군의 평균 치료기간은 $1.37{\pm}0.92$년, 2군은 $0.41{\pm}0.08$년이었고, 전체적으로는 $0.89{\pm}0.81$년이었다. 치료 시작시 두군 간에 역연령, 골연령, 신장, 표적키, 예측성인신장, 혈청 IGF-1 및 IGFBP-3 치의 차이는 없었고, 마지막 추적시 두 군간에 역연령, 골연령, 신장, 예측성인신장, 혈청 IGF-1 및 IGFBP-3치의 차이도 없었다. 두 군 사이에 성장속도와 치료기간에 따른 예측성인신장의 증가분은 2군이 의미 있게 높았다. 이는 2군이 치료기간이 짧아 사춘기의 성장속도가 충분히 억제되지 않은 결과로 보인다. 치료 시작시에 비하여 마지막 추적시의 예측성인신장은 의미 있게 증가하여 단기간의 치료에도 어느 정도의 효과($3.7{\pm}3.2cm$)는 있었다. 전체 대상아에서 표적키($157.3{\pm}3.1cm$)와 치료 시작시 예측성인신장($148.5{\pm}5.8cm$) 사이에는 의미있는 차이가 있었으며, 마지막 추적시의 예측성인신장($152.2{\pm}5.9cm$) 사이에도 의미 있는 차이가 있었다. 검사 소견에서 혈청 IGF-1과 IGFBP-3는 치료 시작시에 비하여 마지막 추적시에는 의미 있게 감소하여 GnRHa의 사용으로 성장호르몬-IGF 축이 다소간 억제되는 것으로 보인다. 결 론 : 사춘기가 조기에 시작하여 골연령이 역연령에 비하여 증가되어 예측성인신장이 표적키에 못 미치는 경우에 단기간의 GnRHa의 사용으로 예측성인신장은 다소 증가하였으나 표적키에는 미치지 못함을 알 수 있었으며, 성장호르몬-IGF 축의 억제가 동반되는 점에서 GnRHa 치료시 예측성인신장이 표적키에 이르기 위해서는 성장호르몬의 동시 사용이 필요하겠다.

Keywords

Acknowledgement

Supported by : 충북대학교

References

  1. Crowley WF Jr, Comite F, Vale W, Rivier J, Loriaux DL, Cutler GB Jr. Therapeutic use of pituitary desensitization with a long-acting LHRH agonist : a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1981;52:370-2 https://doi.org/10.1210/jcem-52-2-370
  2. Antoniazzi F, Zamboni G. Central precocious puberty : current treatment options. Paediatr Drugs 2004;6:211-31 https://doi.org/10.2165/00148581-200406040-00002
  3. Saenger P, Rincon M. Precocious puberty : McCune- Albright syndrome and beyond. J Pediatr 2003;143:9-10 https://doi.org/10.1016/S0022-3476(03)00272-5
  4. Tuvemo T, Proos LA. Girls adopted from developing countries : a group at risk of early pubertal development and short final height. Implications for health surveillance and treatment. Ann Med 1993;25:217-9 https://doi.org/10.3109/07853899309147867
  5. Bayley N, Pimenan SR. Tables for predicting adult height from skeletal age : revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423-41 https://doi.org/10.1016/S0022-3476(52)80205-7
  6. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Standford. California : Standford univ. press, 1993
  7. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291-303 https://doi.org/10.1136/adc.44.235.291
  8. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13-23 https://doi.org/10.1136/adc.45.239.13
  9. Partsch CJ, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol 2002; 56:129-48 https://doi.org/10.1046/j.0300-0664.2001.01490.x
  10. Bath LE, Brown DC, Kelnar CJH. Precocious puberty. Current Paediatr 1999;9:242-6 https://doi.org/10.1054/cupe.1999.0061
  11. Stanhope R, Brook CC. Thelarche variant : a new syndrome of precocious sexual maturation- Acta Endocrinol 1990;123: 481-6
  12. Cisternino M, Arrigo T, Pasquino AM, Tinelli C, Antoniazzi F, Beduschi L, et al. Etiology and age incidence of precocious puberty in girls : a multicentric study. J Pediatr Endocrinol Metab 2000;13 Suppl 1:695-701
  13. Midyett LK, Moore WV, Jacobson JD. Are pubertal changes in girls before age 8 benign? Pediatrics 2003;111:47-51 https://doi.org/10.1542/peds.111.1.47
  14. Gunther DF, Calikoglu AS, Underwood LE. The effects of the estrogen receptor blocker, Faslodex(ICI 182,780), on estrogen- accelerated bone maturation in mice. Pediatr Res 1999;46:269-73 https://doi.org/10.1203/00006450-199909000-00004
  15. Roger M, Chaussain JL, Berlier P, Bost M, Canlorbe P, Colle M, et al. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules. J Clin Endocrinol Metab 1986;62: 670-7 https://doi.org/10.1210/jcem-62-4-670
  16. Laron Z, Kauli R. Experience with cyproterone acetate in the treatment of precocious puberty. J Pediatr Endocrinol Metab 2000;13 Suppl 1:805-10
  17. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, et al. Final height after long-term treatment with triptorelin slow release for central precocious puberty : importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J Clin Endocrinol Metab 1999;84:1973-8 https://doi.org/10.1210/jc.84.6.1973
  18. Antoniazzi F, Cisternino M, Nizzoli G, Bozzola M, Corrias A, De Luca F, et al. Final height in girls with central precocious puberty : comparison of two different luteinizing hormone-releasing hormone agonist treatments. Acta Paediatr 1994;83:1052-6 https://doi.org/10.1111/j.1651-2227.1994.tb12984.x
  19. Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F, et al. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 1999;141:140-4 https://doi.org/10.1530/eje.0.1410140
  20. Oerter KE, Manasco PK, Barnes KM, Jones J, Hill S, Cutler GB Jr. Effects of luteinizing hormone-releasing hormone agonists on final height in luteinizing hormone-releasing hormone-dependent precocious puberty. Acta Paediatr Suppl 1993;388:62-8
  21. Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzelan A, Laron Z. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method. Horm Res 1997; 47:54-61 https://doi.org/10.1159/000185432
  22. Mul D, Bertelloni S, Carel JC, Saggese G, Chaussain JL. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty : final height results. Horm Res 2002;58:1-7 https://doi.org/10.1159/000063209
  23. Adan L, Chemaitilly W, Trivin C, Brauner R. Factors predicting adult height in girls with idiopathic central precocious puberty : implications for treatment. Clin Endocrinol 2002;56:297-302 https://doi.org/10.1046/j.1365-2265.2002.01488.x
  24. Ohyama K, Tanaka T, Tachibana K, Niimi H, Fujieda K, Matsuo N, et al. Timing for discontinuation of treatment with a long-acting gonadotropin-releasing hormone analog in girls with central precocious puberty. TAP-144SR CPP Study Group. Endocr J 1998;45:351-6 https://doi.org/10.1507/endocrj.45.351
  25. Cassio A, Cacciari E, Balsamo A, Bal M, Tassinari D. Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years. Arch Dis Child 1999;81:329-32 https://doi.org/10.1136/adc.81.4.329
  26. Bouvattier C, Coste J, Rodrigue D, Teinturier C, Carel JC, Chaussain JL, et al. Lack of effect of GnRH agonists on final height in girls with advanced puberty : a randomized long-term pilot study. J Clin Endocrinol Metab 1999;84: 3575-8 https://doi.org/10.1210/jc.84.10.3575
  27. Couto-Silva AC, Adan L, Trivin C, Brauner R. Adult height in advanced puberty with or without gonadotropin hormone releasing hormone analog treatment. J Pediatr Endocrinol Metab 2002;15:297-305
  28. Tato L, Saggese G, Cavallo L, Antoniazzi F, Corrias A, Pasquino AM, et al. Use of combined Gn-RH agonist and hGH therapy for better attining the goals in precocious puberty treatment. Horm Res 1995;44 Suppl 3:49-54 https://doi.org/10.1159/000184674
  29. Pasquino AM, Municchi G, Pucarelli I, Segni M, Mancini MA, Troiani S. Combined treatment with gonadotropin-releasing hormone analog and growth hormone in central precocious puberty. J Clin Endocrinol Metab 1996;81:948-51 https://doi.org/10.1210/jc.81.3.948
  30. Pasquino AM, Pucarelli I, Segni M, Matrunola M, Cerroni F. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. J Clin Endocrinol Metab 1999;84:449-52 https://doi.org/10.1210/jc.84.2.449
  31. Tuvemo T, Gustafsson J, Proos LA. Growth hormone treatment during suppression of early puberty in adopted girls. Swedish Growth Hormone Advisory Group. Acta Paediatr 1999;88:928-32 https://doi.org/10.1080/08035259950168388
  32. Mul D, Oostdijk W, Waelkens JJ, Schulpen TW, Drop SL. Gonadotrophin releasing hormone agonist treatment with or without recombinant human GH in adopted children with early puberty. Clin Endocrinol 2001;55:121-9 https://doi.org/10.1046/j.1365-2265.2001.01315.x